| Change in substantial holding | Nov 19, 2026 | Ownership change notice | ASX |
|---|
| Quarterly Activities/Appendix 4C Cash Flow Report | Oct 30, 2026 | Quarterly report | ASX |
|---|
| Quarterly Activities/Appendix 4C Cash Flow Report | Oct 30, 2026 | Quarterly report | ASX |
|---|
| Additional $750,000 Loan Facility from Barvest Ventures | Oct 30, 2026 | Financing | ASX |
|---|
| Notice of Annual General Meeting/Proxy Form | Oct 28, 2026 | Meeting notice | ASX |
|---|
| Partnership with Florida Lung, Asthma & Sleep Specialists | Oct 25, 2026 | Operations update | ASX |
|---|
| Appointment of Chief Financial Officer | Oct 11, 2026 | Management or board change | ASX |
|---|
| AUD$700,000 Short-Term Loan Facility from Barvest Ventures | Oct 6, 2026 | Other filings | ASX |
|---|
| Appendix 4G & Corporate Governance Statement | Sep 30, 2026 | Other filings | ASX |
|---|
| Annual Report to shareholders | Sep 30, 2026 | Annual report | ASX |
|---|
| Adherium Consolidates Funding into A$4.67M Term Loan | Sep 15, 2026 | Financing | ASX |
|---|
| Preliminary Final Report | Aug 31, 2026 | Annual report | ASX |
|---|
| Change of Company Secretary | Aug 21, 2026 | Management or board change | ASX |
|---|
| Adherium enters into additional $1M short-term loan facility | Aug 17, 2026 | Financing | ASX |
|---|
| Ceasing to be a substantial holder | Jul 30, 2026 | Ownership change notice | ASX |
|---|
| Adherium Announces CEO Transition | Jul 28, 2026 | Management or board change | ASX |
|---|
| Quarterly Activities/Appendix 4C Cash Flow Report | Jul 28, 2026 | Quarterly report | ASX |
|---|
| Adherium - Investor Update | Jul 26, 2026 | Other filings | ASX |
|---|
| Results of Extraordinary General Meeting | Jun 18, 2026 | Meeting outcome | ASX |
|---|
| Notice of Share Consolidation | May 20, 2026 | Other filings | ASX |
|---|
| Adherium Hailie Smartinhaler Quarter-to-Date Sales Update | Mar 10, 2026 | Results | ASX |
|---|
| Half Yearly Report and Accounts | Feb 27, 2026 | Interim report | ASX |
|---|
| Completion of Placement and Institutional Entitlement Offer | Feb 17, 2026 | Financing | ASX |
|---|
| Placement and Accelerated Non-Renounceable Entitlement Offer | Feb 15, 2026 | Financing | ASX |
|---|
| Equity Raising Investor Presentation | Feb 15, 2026 | Financing | ASX |
|---|
| Trading Halt | Feb 15, 2026 | Trading halt or suspension | ASX |
|---|
| Quarterly Activities/Appendix 4C Cash Flow Report | Jan 30, 2026 | Quarterly report | ASX |
|---|
| Adherium exceeds CY2025 device shipment milestones | Dec 23, 2025 | Results | ASX |
|---|
| Adherium quarter to date sales update | Dec 15, 2025 | Results | ASX |
|---|
| Adherium reaches major milestone in Allergy Partners rollout | Nov 26, 2025 | Operations update | ASX |
|---|
| iCARE Study Hailie Smartinhaler Improves Patient Adherence | Sep 15, 2025 | Results | ASX |
|---|
| Preliminary Final Report | Aug 29, 2025 | Results | ASX |
|---|
| Firm commitments received for institutional placement | Aug 4, 2025 | Financing | ASX |
|---|
| Adherium Appoints Dawn Bitz as CEO | Jul 22, 2025 | Management or board change | ASX |
|---|
| Successful Completion of Retail Component of ANREO | Jul 17, 2025 | Financing | ASX |
|---|
| Replacement Prospectus | Jun 26, 2025 | Offer document | ASX |
|---|
| Successful Completion of Institutional Component of ANREO | Jun 26, 2025 | Financing | ASX |
|---|
| Prospectus | Jun 24, 2025 | Offer document | ASX |
|---|
| Accel Non-Renounceable Entitlement Offer to raise up to $4m | Jun 24, 2025 | Financing | ASX |
|---|
| $900K Capital Raise to Accelerate Smart Inhaler in US | May 19, 2025 | Financing | ASX |
|---|
| Adherium Secures $2.6M to Advance Smart Inhaler in US | Mar 18, 2025 | Financing | ASX |
|---|
| Management Change | Oct 29, 2024 | Other filings | ASX |
|---|
| AstraZeneca selected Adherium Smartinhaler for its study | May 23, 2024 | Operations update | ASX |
|---|
| Non-Renounceable Rights Issue Offer Completes | May 23, 2024 | Financing | ASX |
|---|
| Placement and Entitlement Offer to raise up to $8.37 million | Apr 26, 2024 | Financing | ASX |
|---|
| First Patient Enrolled in Major e-health Clinical Study | Mar 19, 2024 | Operations update | ASX |
|---|
| Adherium receives $1.5m Australian R&D Tax Rebate | Mar 6, 2024 | Results | ASX |
|---|
| New CEO Appointed - Dr Paul Mastoridis | Jan 31, 2024 | Management or board change | ASX |
|---|
| Resignation of CEO | Jan 15, 2024 | Management or board change | ASX |
|---|
| Notice of Annual General Meeting/Proxy Form | Oct 26, 2023 | Meeting notice | ASX |
|---|
| Annual Report to shareholders | Aug 30, 2023 | Annual report | ASX |
|---|
| Adherium SPP and Shortfall Offers Prospectus | Nov 17, 2022 | Offer document | ASX |
|---|
| Adherium secures $13.5m in placement commitments | Sep 16, 2022 | Financing | ASX |
|---|
| Adherium signs UK distribution agreement with Helicon Health | Jun 14, 2022 | Other filings | ASX |
|---|
| Adherium to support Avillion sponsored clinical study | Jun 1, 2022 | Other filings | ASX |
|---|
| Adherium awarded US-based AZ clinical study supply contract | Sep 24, 2021 | Other filings | ASX |
|---|
| Target's Statement | Jun 28, 2021 | Offer document | ASX |
|---|
| Letter to Shareholders re takeover offer | Jun 16, 2021 | Acquisition or disposal | ASX |
|---|
| Adherium submits next gen sensor for US FDA clearance | May 31, 2021 | Other filings | ASX |
|---|
| Replacement Bidders Statement | May 27, 2021 | Offer document | ASX |
|---|
| 1st Supplementary Bidder's Statement(marked up replacement | May 27, 2021 | Offer document | ASX |
|---|
| Adherium announces new CEO and Board appointments | May 12, 2021 | Management or board change | ASX |
|---|
| Adherium Directors' Statement re Takeover | May 10, 2021 | Acquisition or disposal | ASX |
|---|
| Appendix 4C - quarterly | Apr 30, 2021 | Quarterly report | ASX |
|---|
| Adherium response to Respiri announcement | Apr 29, 2021 | Other filings | ASX |
|---|
| Bidder's Statement | Apr 29, 2021 | Offer document | ASX |
|---|
| Adherium investor presentation | Mar 17, 2021 | Other filings | ASX |
|---|
| Adherium secures $18m share placement commitment | Mar 17, 2021 | Financing | ASX |
|---|
| Adherium agrees rollout to specialist US respiratory centres | Nov 23, 2020 | Other filings | ASX |
|---|
| Adherium secures $3m funding from Viburnum | Oct 25, 2020 | Other filings | ASX |
|---|
| CEO update presentation to the EGM | Jul 23, 2020 | Other filings | ASX |
|---|
| Adherium $5m raise with BioScience Managers Translation Fund | May 25, 2020 | Other filings | ASX |
|---|
| Adherium progresses US sales agreement with Monaghan Medical | Apr 29, 2020 | Other filings | ASX |
|---|
| Adherium appoints Mike Motion CEO/Director and Anne Bell CFO | Apr 24, 2020 | Other filings | ASX |
|---|
| Adherium and Planet Innovation partner in tech development | Apr 21, 2020 | Other filings | ASX |
|---|
| Adherium announces collaboration with HGE Health in COPD | Apr 16, 2020 | Other filings | ASX |
|---|
| Adherium Completes $5.4m Capital Raise | Feb 10, 2020 | Other filings | ASX |
|---|
| Adherium December 2019 Update Presentation | Dec 18, 2019 | Other filings | ASX |
|---|
| Adherium Non-renounceable Rights Issue Offer Document | Dec 18, 2019 | Financing | ASX |
|---|
| Adherium announces Non-Renounceable Issue | Dec 10, 2019 | Other filings | ASX |
|---|
| Adherium appoints Peter Stratford CEO and Mike Motion CCO | Nov 21, 2019 | Other filings | ASX |
|---|
| Adherium and Patients Know Best strategic collaboration | Nov 17, 2019 | Other filings | ASX |
|---|
| Amended - Adherium announces $1.1m notes financing | Nov 11, 2019 | Other filings | ASX |
|---|
| Response to ASX Query | Nov 10, 2019 | Explanation request | ASX |
|---|
| Adherium announces $1.8m secured notes financing | Aug 21, 2019 | Other filings | ASX |
|---|
| Adherium and Summatix announce strategic initiative | Aug 20, 2019 | Other filings | ASX |
|---|
| Adherium Receives further U.S. 510k Clearances | Jul 15, 2019 | Other filings | ASX |
|---|
| Employee Share Plan buy-back - Appendix 3C | May 24, 2019 | Treasury share status | ASX |
|---|
| Response to Appendix 4C Query | May 6, 2019 | Quarterly report | ASX |
|---|
| Adherium Restructures for Growth | Dec 12, 2018 | Other filings | ASX |
|---|
| Adherium Investor Conference Call Presentation | Oct 30, 2018 | Other filings | ASX |
|---|
| Adherium and Vitalus Health Launch Commercial Program | Aug 23, 2018 | Other filings | ASX |
|---|
| Adherium Receives Additional US FDA 510(k) Clearance | Jul 26, 2018 | Other filings | ASX |
|---|
| Adherium Program with Connecticut Childrens Medical Center | Jul 10, 2018 | Other filings | ASX |
|---|
| Adherium Smartinhaler used in Global Mild-Asthma Studies | May 21, 2018 | Other filings | ASX |
|---|
| Adherium launches new global brand Hailie | May 16, 2018 | Other filings | ASX |
|---|
| Adherium Announces Program with Vitalus Health | May 1, 2018 | Other filings | ASX |
|---|
| Adherium receives US FDA 510k OTC clearance | Mar 27, 2018 | Other filings | ASX |
|---|
| Asthma Adherence Management Findings | Mar 7, 2018 | Other filings | ASX |
|---|
| Adherium Highlights Milestones Achieved | Dec 20, 2017 | Other filings | ASX |
|---|
| Presentation to AGM | Nov 29, 2017 | Other filings | ASX |
|---|
| Adherium receives US FDA 510k clearance | Aug 31, 2017 | Other filings | ASX |
|---|
| Investor Conference Call Presentation | Aug 28, 2017 | Other filings | ASX |
|---|
| Commitments Test Entity - Fourth Quarter Report | Jul 31, 2017 | Other filings | ASX |
|---|
| Adherium Appoints New CEO to Drive Global Growth | Jun 8, 2017 | Management or board change | ASX |
|---|
| Appendix 4C - quarterly December 2016 | Jan 29, 2017 | Quarterly report | ASX |
|---|
| NICE reports on Adherium Smartinhaler for asthma management | Jan 11, 2017 | Other filings | ASX |
|---|
| Adherium Smartinhaler dramatically improves outcomes | Nov 17, 2016 | Other filings | ASX |
|---|
| Appendix 4C - quarterly for period ended 30 Sept 2016 | Oct 31, 2016 | Quarterly report | ASX |
|---|
| Key Technology Patent Granted in US | Oct 19, 2016 | Other filings | ASX |
|---|
| Adherium and AstraZeneca Australia Commercial Pilot Program | Aug 16, 2016 | Other filings | ASX |
|---|
| Adherium Executes Placement to Fidelity International | Jul 19, 2016 | Financing | ASX |
|---|
| Adherium Smartinhaler in AstraZeneca COPD Study | Jun 13, 2016 | Other filings | ASX |
|---|
| Clearance to Market in Canada for Flagship Products | Mar 15, 2016 | Other filings | ASX |
|---|
| Appendix 4D and Interim Consolidated Financial Report | Feb 29, 2016 | Interim report | ASX |
|---|
| Adherium Smartinhaler Technology in Multinational Study | Feb 26, 2016 | Other filings | ASX |
|---|
| New Clinical Data Presented at ERS 2015 | Feb 11, 2016 | Other filings | ASX |
|---|
| Admission to Official List | Feb 10, 2016 | Other filings | ASX |
|---|